Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HALAVEN vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Halaven (eribulin mesylate) is a microtubule dynamics inhibitor. It binds to tubulin, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, leading to G2/M cell cycle arrest and apoptosis.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Metastatic breast cancer in patients who have received at least two prior chemotherapy regimens including an anthracycline and a taxane,Unresectable or metastatic liposarcoma in patients who have received a prior anthracycline-containing regimen
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life approximately 30-50 hours (mean 40 hours). Clinically, this supports weekly dosing schedule.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Eribulin is primarily metabolized by CYP3A4 with minor contributions from other CYP isoforms. It undergoes minimal hepatic metabolism and is predominantly excreted unchanged in bile and feces.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily biliary/fecal: ~70-80% as unchanged drug and metabolites in feces; renal excretion accounts for <10% (mostly metabolites).
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Approximately 87-95% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 85-90% bound to serum albumin.
Vd approximately 32-48 L/m² (approx. 0.9-1.4 L/kg, assuming 70 kg). Large Vd indicates extensive tissue distribution.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Only intravenous route available; no oral bioavailability data as it is not administered orally.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
For creatinine clearance 30-50 m L/min: 1.1 mg/m2 on days 1 and 8 of a 21-day cycle. For creatinine clearance <30 m L/min: not recommended.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh A: 1.1 mg/m2 on days 1 and 8 of a 21-day cycle. Child-Pugh B: 0.7 mg/m2 on days 1 and 8 of a 21-day cycle. Child-Pugh C: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Safety and efficacy not established in pediatric patients.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment recommended; monitor for toxicity.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
No FDA boxed warning.
None.
Neutropenia: monitor complete blood counts prior to each dose; dose reduce or delay as needed,Peripheral neuropathy: monitor for neuropathy, dose reduce or discontinue if severe,QT prolongation: monitor ECG in patients with heart failure, bradyarrhythmias, or electrolyte abnormalities,Embryo-fetal toxicity: can cause fetal harm, advise effective contraception
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to eribulin or any components of the formulation
Hypersensitivity to AURLUMYN or any of its components.
Avoid grapefruit and grapefruit juice as they may increase eribulin levels.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
FDA Pregnancy Category D. Based on its mechanism of action (microtubule inhibitor) and animal studies, HALAVEN can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, eribulin was embryotoxic and fetotoxic at doses below the recommended human dose. There are no adequate and well-controlled studies in pregnant women. If used during pregnancy or if the patient becomes pregnant while receiving this drug, apprise the patient of the potential hazard to the fetus. Avoid use during the first trimester due to high risk of teratogenicity; use during second and third trimesters may cause fetal growth restriction and oligohydramnios.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
It is not known whether eribulin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from HALAVEN, advise women not to breastfeed during treatment and for at least 2 weeks after the last dose. No M/P ratio available.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No specific dosing adjustments for pregnancy have been established. Physiological changes during pregnancy (e.g., increased plasma volume, renal clearance) may alter eribulin pharmacokinetics, but no data exist. Use the standard dose of 1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle, with dose adjustments based on toxicity (e.g., neutropenia, thrombocytopenia, hepatic impairment) rather than pregnancy status.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Halaven (eribulin) is a nontaxane microtubule inhibitor used in metastatic breast cancer and liposarcoma. Monitor for neutropenia, peripheral neuropathy, and QT prolongation. Dose reduction required for moderate hepatic impairment (Child-Pugh B). Administer intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle. Antiemetic prophylaxis recommended.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
This drug can lower your white blood cell count, increasing infection risk. Report fever or chills immediately.,You may experience numbness, tingling, or weakness in your hands or feet; notify your doctor if these occur.,Halaven can cause fatigue, nausea, and hair loss; supportive care is available.,Avoid grapefruit and grapefruit juice during treatment due to potential interaction.,Use effective contraception during treatment and for at least 2 weeks after the last dose.,Do not breastfeed while taking this medication.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HALAVEN vs AURLUMYN, answered by our medical review team.
HALAVEN is a Antineoplastic Agent that works by Halaven (eribulin mesylate) is a microtubule dynamics inhibitor. It binds to tubulin, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, leading to G2/M cell cycle arrest and apoptosis.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HALAVEN and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HALAVEN is: 1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HALAVEN and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HALAVEN is classified as Category C. FDA Pregnancy Category D. Based on its mechanism of action (microtubule inhibitor) and animal studies, HALAVEN can cause fetal harm when administered to a pregnant woman. In animal. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.